← Back to Search

Small Molecule Inhibitor

AMG 337 for Clear Cell Sarcoma of Soft Tissue

Phase 2
Waitlist Available
Research Sponsored by NantPharma, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing AMG 337, a medication, in patients with advanced or metastatic clear cell sarcoma that has a specific genetic change. The goal is to see if the medication can stop the cancer cells from growing by blocking their internal communication systems. AMG 337 is taken orally and targets specific cancer cells.

Eligible Conditions
  • Clear Cell Sarcoma of Soft Tissue

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective Response Rate (ORR)
Secondary study objectives
Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AMG 337Experimental Treatment1 Intervention
AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 337
2014
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

NantPharma, LLCLead Sponsor
2 Previous Clinical Trials
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top